• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Revolutionary Drug That’s “Closest Thing” To HIV Vaccine Gets FDA Approval

June 19, 2025 by Deborah Bloomfield

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. The drug, which is being marketed by Gilead Sciences as Yeztugo, has shown a 99.9 percent prevention rate in a clinical trial involving people of all genders.

The creation of an HIV vaccine has been difficult due to the complex nature of the virus, but the development of PrEP has given people a tool to protect themselves from HIV infections. Lenacapavir comes as two injections given six months apart, unlike PrEP, which is usually taken as daily pills.

PrEP and now lenacapavir have come along during a momentous progression in the prevention and treatment of HIV in recent decades. A crucial breakthrough has been the ability of new drugs to lead to undetectable levels of the virus, making it impossible for it to be passed along.

“This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, said in a statement.

“This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention. Gilead scientists have made it their life’s work to end HIV and now, with the FDA approval of Yeztugo and in collaboration with our many partners, we can help to make that goal a reality.”

The revolutionary drug comes with a very high price tag of $14,109 per injection. While Gilead stated that it is working with insurers and healthcare providers to ensure broad insurance coverage for the drug, many have pointed out that there is research showing that lenacapavir could be made up to 1,000 times cheaper than its current market price.

“This is a breakthrough moment. The approval of lenacapavir is a testament to decades of public investment, scientific excellence, and the contributions of trial participants and communities. I congratulate Gilead and US partners for advancing this important innovation. Lenacapavir could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit,” Winnie Byanyima, Executive Director of UNAIDS and United Nations Undersecretary-General, said in a statement.

“UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218. If this game-changing medicine remains unaffordable, it will change nothing. I urge Gilead to do the right thing. Drop the price, expand production, and ensure the world has a shot at ending AIDS.”

HIV and AIDS are responsible for the deadliest pandemic in living memory, which has claimed the lives of 42.3 million people since the 1980s. About 39.9 million people across the globe were living with HIV in 2023, but thanks to improved medicine and improved equitable access to it, annual AIDS-related fatalities have declined by 51 percent since 2010.

Breakthrough drugs show that it is very possible to end HIV in a matter of years, as long as there is an interest in creating equal access to those very drugs.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Lyft will pay legal fees for drivers sued under Texas abortion ban – CEO
  2. Alphabet gives some Loon patents to SoftBank, open sources flight data and makes patent non-assertion pledge
  3. Hurricane Milton Doubling In Size, Set To Be One Of The Most Destructive Atlantic Storms
  4. Pollution Related To Space Is Getting Worse As Trump And Musk Target Research And Regulations

Source Link: Revolutionary Drug That's “Closest Thing” To HIV Vaccine Gets FDA Approval

Filed Under: News

Primary Sidebar

  • 24-Million-Year-Old Protein Fragments Are Oldest Ever Recovered, A Robot Listened To Spoken Instructions And Performed Surgery, And Much More This Week
  • DNA From Greenland Sled Dogs – Maybe The World’s Oldest Breed – Reveals 1,000 Years Of Arctic History
  • Why Doesn’t Moonrise Shift By The Same Amount Each Night?
  • Moa De-Extinction, Fashionable Chimps, And Robot Surgery – No Human Required
  • “Human”: Powerful New Images Mark The Most Scientifically Accurate “Hyper-Real 3D Models Of Human Species Ever”
  • Did We Accidentally Leave Life On The Moon In 2019 – And Could We Revive It?
  • 1.8 Million Years Ago, Two Extinct Humans Had One Of The Gnarliest Deaths In History
  • “Powerful Image” Of One Of The World’s Rarest Tigers Exposes The Real Danger In Taman Negara
  • Evolution, Domestication, And A Lot Of Very Good Boys: How Wolves Became Dogs
  • Why Do Orcas Have White Spots Near Their Eyes?
  • Tomb Of First King Of Ancient Maya City Discovered In Belize
  • The Real Reason The Tip Of Your Tape Measure Wiggles Like That
  • The “Haunting” Last Message From NASA’s Opportunity Rover, Sent From Inside A Planet-Wide Storm
  • Adorable Video Proves Not All Gorillas Hate The Rain. It Might Even Win One A Mate
  • 5,000-Year-Old Rock Art May Show One Of Ancient Egypt’s First Rulers
  • Alzheimer’s-Linked Protein Levels “20 Times Higher” In Newborn Babies – What Does This Mean?
  • Americans Were Asked If They Thought Civil War Was Coming. The Results Were Unexpected
  • Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology
  • Dams Have Nudged Earth’s Poles By Over 1 Meter In The Past 200 Years
  • This Sugar Could Be A Cure For Male Pattern Baldness – And It’s Been In Our Bodies All Along
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version